← Back to Clinical Trials
RecruitingPhase 2NCT06590896
Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
◆ AI Clinical Summary
Plain-language summary for patients
Trial Parameters
ConditionEpilepsies, Partial
SponsorOno Pharmaceutical Co. Ltd
Study TypeINTERVENTIONAL
PhasePhase 2
Enrollment100
SexALL
Min AgeN/A
Max AgeN/A
Start Date2022-11-04
Completion2027-01-31
Interventions
Cenobamate
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
To evaluate the long-term safety and tolerability of cenobamate in Japanese epilepsy patients with partial seizures
Eligibility Criteria
Inclusion Criteria: * Subjects completed Study YKP3089C035 by SK Life Science. Exclusion Criteria: * Subjects that have previously discontinued for any reason from the Core study (YKP3089C035). * Any significant changes to the medical history of the subject that in the opinion of the investigator, could affect the safety of the subject.